FDA Orange Book · active-ingredient family
Azelastine hydrochloride; fluticasone propionate
Azelastine hydrochloride; fluticasone propionate is approved as 1 brand and 3 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:DYMISTA · NDA 202236
1
Brand (NDA)
3
Generics (ANDA)
2
Listed patents
0
Exclusivity periods
Brand (NDA) products · spray, metered
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| DYMISTARLD | MYLAN SPECIALITY LP | NDA 202236 | AB | May 01, 2012 |
Generic (ANDA) products (3)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE | TEVA PHARMS USA INC | ANDA 208436 | AB | Apr 08, 2025 | |
| AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE | PADAGIS ISRAEL | ANDA 208111 | AB | Feb 18, 2021 | |
| AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE | APOTEX | ANDA 207712 | AB | Apr 28, 2017 |
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8168620 | Feb 24, 2026 | 4 mo ago | Product |
| 8168620*PED | Aug 24, 2026 | in 2 mo |
Azelastine hydrochloride; fluticasone propionate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

